Progress in diagnosis and treatment of multiple myeloma patients with renal impairment

doi:10.3877/cma.j.issn.2095-3216.2017.05.002

Abstract

Abstract:

Multiple myeloma (MM) refers to a malignant proliferative disorder caused by abnormal proliferation of plasma cells in the bone marrow, which is characterized by the production of monoclonal immunoglobulins or their fragments that subsequently lead to damage to the relevant organs or tissues. Renal damage is a common complication of MM, and is one of the main causes of death. There are various mechanisms of renal damage in MM, among which tubular nephropathy and hypercalcaemia are most important. Timely and effective diagnosis and appropriate treatment plans can improve the overall prognosis of such patients. This article focused on the diagnosis and treatment of myeloma-related renal damage.

Key words: Multiple myeloma, Renal impairment, Serum free light chain, High cut-off hemodialysis

Yonghui Mao, Songlan Wang. Progress in diagnosis and treatment of multiple myeloma patients with renal impairment[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2017, 06(05): 195-199.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2017.05.002

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2017/V06/I05/195

Figures/Tables 1

References 35

[1]	Kariyawasan CC, Hughes DA, Jayatillake MM, et al. Multiple myeloma: causes and consequences of delay in diagnosis [J]. QJM, 2007, 100(10): 635-639.
[2]	Knudsen LM, Hippe E, North M, et al. Renal function in newly diagnosed multiple myeloma-a demographic study of 1353 patients. [J]. Eur J Haematol, 1994, 53(4): 207-212.
[3]	Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma [J]. Mayo Clin Proc, 2003, 78(1): 21-24.
[4]	Gonsalves WI, Leung N, Rajkumar SV, et al. Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma [J]. Blood Cancer J, 2015, 5(3): e296-e311.
[5]	Hutchison CA, Plant T, Drayson M, et al. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure [J]. BMC Nephrol, 2008, 9: 11-19.
[6]	Dispenzieri A, Kyle R, Merlini G, et al.International Myeloma Working Group guidelines for serum free light chain analysis in multiple myeloma and related disorders [J]. Leukemia, 2009, 23(2): 215-224.
[7]	Hutchison CA, Plant T, Drayson M, et al. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure [J]. BMC Nephrol, 2008, 9: 11-20.
[8]	Hutchison CA, Harding S, Hewins P, et al. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease [J]. Clin J Am Soc Nephrol, 2008, 3(6): 1684-1690.
[9]	Heher EC, Rennke HG, Laubach JP, et al. Kidney disease and multiple myeloma [J]. Clin J Am Soc Nephrol, 2013, 8(11): 2007-2017.
[10]	Basnayake K, Ying WZ, Wang PX, et al. Immunoglobulin light chains activate tubular epithelial cells through redox signaling [J]. J Am Soc Nephrol, 2010, 21(7): 1165-1173.
[11]	Kleber M, Ihorst G, Deschler B, et al. Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients [J]. Eur J Haematol, 2009, 83(6): 519-527.
[12]	Cockwell P, Hutchison CA. Management options for cast nephropathy in multiple myeloma [J]. Curr Opin Nephrol Hypertens, 2010, 19(6): 550-555.
[13]	Munier A, Gras V, Andrejak M, et al. Zoledronic acid and renal toxicity: data from French adverse effect reporting database [J]. Ann Pharmacother, 2005, 39(7-8): 1194-1197.
[14]	Hiromura K, Nujima Y. Renal disease in multiple myeloma [J]. Nihon Rinsho, 2007, 65(12): 2229-2234.
[15]	Barlogie B, Shaughnessy J, Tricot S, et al. Treatment of multiple myeloma [J]. Blood, 2004, 103(1): 20-22.
[16]	Ludwig H, Adam Z, Hajek R, et al. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin -dexamethasone in multiple myeloma: results of a phase II study [J]. J Clin Oncol, 2010, 28(30): 4635-4642.
[17]	Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase Ⅲ HOVON-65/ GMMG-HD4 trial [J]. J Clin Oncol, 2012, 30(24): 2946-2956.
[18]	Ballester OF, Tummala R, Janssen WE, et al. High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiency [J]. Bone Marrow Transplant, 1997, 20(8): 653-666.
[19]	何东，牛挺．硼替佐米治疗多发性骨髓瘤的应用进展[J]．华西医学，2012，(2): 197-202.
[20]	Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3，open-label，multicentre study [J]. Lancet Oncol, 2016, 17(1): 27-38.
[21]	Assi LK, McIntyre N, Fraser S, et al. The association between polyclonal combined serum free light chain concentration and mortality in individuals with early chronic kidney disease [J]. PLoS One, 2015, 10(7): e0129980.
[22]	Hutchison CA, Cockwell P, Reid S, et al. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies [J]. J Am Soc Nephrol, 2007, 18(3): 886-895.
[23]	Tanner GA, Evan AP, Summerlin PB, et al. Glomerular and proximal tubular morphology after single nephron obstruction [J]. Kidney Int, 1989, 36(6): 1050-1060.
[24]	Leung N, Gertz MA, Zeldenrust SR, et al. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains [J]. Kidney Int, 2008, 73(11): 1282-1288.
[25]	Yu X, Gan L, Wang Z, et al. Chemotherapy with or without plasmapheresis in acute renal failure due to multiple myeloma：a meta-analysis [J]. Int J Clin Pharmacol Ther, 2015, 53(5): 391-397.
[26]	Hutchison CA, Bradwell AR, Cook M, et al. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis [J]. Clin J Am Soc Nephrol, 2009, 4(4): 745-754.
[27]	Hutchison CA, Cockwell P, Reid S. et al. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies [J]. J Am Soc Nephrol, 2007, 18(3): 886-895.
[28]	Martín-Reyes G, Toledo-Rojas R, Torres-de R, et al. Haemodialysis using high cut-off dialysers for treating acute renal failure in multiple myeloma [J]. Nefrologia (Madr), 2012, 32: 35-43.
[29]	Hutchison CA, Heyne N, Airia P, et al. Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemo therapy and high cut-off haemodialysis [J]．Nephrol Dial Transplant, 2012, 27(10): 3823-3828.
[30]	Curti A, Schwarz A, Trachsler J, et al. Therapeutic efficacy and cost effectiveness of high cut-off dialyzers compared to conventional dialysis in patients with cast nephropathy [J]. PLoS One, 2016, 11(7): e0159942.
[31]	Grima DT, Airia P, Attard C, et al. Modelled cost-effectiveness of high cut-off haemodialysis compared to standard haemodialysis in the management of myeloma kidney [J]. Curr Med Res Opin, 2011, 27(2): 383-391.
[32]	Hutchison CA, Cook M, Heyne N, et al. European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomised control trial [J]. Trials, 2008, 9: 55.
[33]	Cook M, Hutchison C, Fifer L, et al. High cut-off haemodilysis (HCO-HD)dose not improve outcomes in myeloma cast nephropathy: results of European trial of free light chain removal by extended haemodilysis in cast nephropathy (EULITE) [J]. Adv Chronic Kidney Dis, 2012, 19(5): 333-341.
[34]	Taheri D, Chehrei A, Fesharakizadeh M, et al. Recurrent multiple myeloma following renal transplantation: a case report [J]. Transplant Proc, 2007, 39(4): 1063-1065.
[35]	Spitzer TR, Sykes M, Tolkoff-Rubin N, et al. Long-term follow up of recipients of combined human leukocyte antigen-matched bone marrow and kidney transplantation for multiple myeloma with end-stage renal disease [J]. Transplantation, 201l, 91(6): 672-676.

Please choose a citation manager

Content to export